News for Healthier Living

AACR: Olaparib and Pembrolizumab Combination Shows Early Promise in Molecularly Selected, Tumor-Agnostic Trial

* Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations * Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

April 27, 2025


May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025